Category: Previous G-BA decisions

Here are the latest G-BA decisions from the G-BA meeting held on 19 March 2026 on the early benefit assessments of Enhertu, Ezmekly, Tevimbra, Lynozyfic, Taltz, Rybrevant, Alhemo, Idefirix, and Ronapreve. A database of all previous G-BA resolutions is available in my store. Enhertu (Trastuzumab deruxtecan); reassessment based on new scientific evidence: Adenocarcinoma of the…

Here are the latest G-BA decisions from the G-BA meeting held on 5 March 2026 on the early benefit assessments of Rezdiffra and Tavneos. A database of all previous G-BA resolutions is available in my store. Rezdiffra (Resmetirome); metabolic dysfunction-associated steatohepatitis (MASH), non-cirrhotic – Additional benefit not proven Tavneos (avacopan); re-evaluation of an orphan drug…

Here are the latest G-BA decisions from the G-BA meeting held on 20 November 2025 on the early benefit assessments of Retsevmo, Scemblix, Tremfya, Xydalba, Translarna, Vydura and Datroway. Retsevmo achieved the highest possible rating – MAJOR ADDITIONAL BENEFIT – in its re-assessment. A database of all previous G-BA resolutions is available in my store. Retsevmo (Selpercatinib); Thyroid…

Here are the latest G-BA decisions from the G-BA meeting held on 4 December 2025 on the early benefit assessments of Opdivo in two new indications. A database of all previous G-BA resolutions is available in my store. Opdivo (Nivolumab); new indication: unresectable or advanced hepatocellular carcinoma, first-line, in combination with ipilimumab – Additional benefit not…

Here are the latest G-BA decisions from the G-BA meeting held on 6 November 2025 on the early benefit assessments of Rinvoq, Prevymis, and Columvi. A database of all previous G-BA resolutions is available in my store. Rinvoq (Upadacitinib); new indication: giant cell arteritis – Hint of minor additional benefit in one of two subgroups…

Here are the latest G-BA decisions from the G-BA meeting held on 16 October 2025 on the early benefit assessments of Kaftrio, Alhemo, Enhertu, Hetronifly, Emcitate, Keytruda, Augtyro, Wainzua, Lytenava, and Vimizin. A database of all previous G-BA resolutions is available in my store. Kaftrio (Ivacaftor/Tezacaftor/Elexacaftor); new indication: Cystic fibrosis, combination treatment with ivacaftor, ≥…

Here are the latest G-BA decisions from the G-BA meeting held on 2 October 2025 on the early benefit assessments of Jaypirca and Breyanzi. A database of all previous G-BA resolutions is available in my store. Jaypirca (pirtobrutinib); new indication: Chronic lymphocytic leukemia (CLL), relapsed or refractory, monotherapy – Hint of minor additional benefit in…

Here are the latest G-BA decisions from the G-BA meeting held on 21 August 2025 on the early benefit assessments of Beyfortus, Andembry, Darzalex, Blincyto, Imcivree, Inrebic, Obgemsa, Aquipta, and Fabhalta – quite a mixed bag. The G-BA accepted an ITC and an evidence transfer from older to younger children! A database of all previous…

Here are the latest G-BA decisions from the G-BA meeting held on 7 August 2025 on the early benefit assessments of Sarclisa, Jemperli, Jaypirca, Kevzara, Kavigale, Ofev, Vocabria, and Nemluvio – only one minor additional benefit, otherwise all negative… A complete database of all previous G-BA resolutions is available in my membership. ​Sarclisa (isatuximab); new indication:…

Here are the latest G-BA decisions from the G-BA meeting held on 17 July 2025 on the early benefit assessments of Rybrevant, Lazcluze, Pedmarqsi, and Hympavzi. A complete database of all previous G-BA resolutions is in my membership. ​Rybrevant (amivantamab); new indication: non-small cell lung cancer, EGFR exon 19 deletions or exon 21 substitution mutations…